Real-World Effectiveness Study of Nirmatrelvir-Ritonavir or Molnupiravir in Hospitalized Unvaccinated Patients with Chronic Respiratory Diseases and Moderate COVID-19 at Presentation

International Journal of COPD, Год журнала: 2024, Номер Volume 19, С. 77 - 86

Опубликована: Янв. 1, 2024

Introduction: Nirmatrelvir-ritonavir (NMV-r) and molnupiravir (MOL) were developed as out-patient anti-viral for mild COVID-19. There was limited data on their role in treating COVID-19 hospitalized patients, especially among adult patients who are unvaccinated had chronic respiratory diseases. Methods: A territory-wide retrospective study conducted Hong Kong to compare the efficacy of NMV-r MOL against with asthma, obstructive pulmonary disease, bronchiectasis interstitial lung diseases presenting moderate from 16th February 2022 15th March 2023. Results: total 1354 included, 738 received 616 MOL. more effective reducing 90-day mortality adjusted hazard ratios (aHR) 0.508 (95% confidence interval [CI] = 0.314– 0.822, p 0.006). Patients also significantly shorter length stay (LOS) than those receiving MOL, median LOS 4 (Interquartile range [IQR] 2– 7) 6 (IQR 3– 10) (p-value < 0.001). no statistically significant difference development failure severe two groups. Discussion: adults without hypoxaemia admission. Keywords: COPD, bronchiectasis, molnupiravir, nirmatrelvir-ritonavir,

Язык: Английский

---

Clinical effectiveness of nirmatrelvir plus ritonavir in patients with COVID‐19 and substance use disorders based on real‐world data

Journal of Medical Virology, Год журнала: 2023, Номер 95(5)

Опубликована: Май 1, 2023

Abstract This study assessed the clinical efficacy of nirmatrelvir plus ritonavir (NMV‐r) in treating patients with coronavirus disease‐2019 (COVID‐19) and substance use disorders (SUDs). included two cohorts: first examined SUDs, without a prescription for NMV‐r, while second compared prescribed diagnosis SUDs. SUDs were defined using ICD‐10 codes, related to including alcohol, cannabis, cocaine, opioid, tobacco (TUD). Patients underlying COVID‐19 identified TriNetX network. We used 1:1 propensity score matching create balanced groups. The primary outcome interest was composite all‐cause hospitalization or death within 30 days. Propensity yielded matched groups 10 601 each. results showed that NMV‐r associated lower risk death, days after (hazard ratio (HR), 0.640; 95% confidence interval (CI): 0.543–0.754), as well (HR, 0.699; CI: 0.592–0.826) 0.084; 0.026–0.273). However, had higher hospitalized than those even 1.783; 1.399–2.271). also found prevalence comorbidities adverse socioeconomic determinants health Subgroup analysis benefits consistent across most subgroups different characteristics, age (patients aged ≥60 years [HR, 0.507; 0.402–0.640]), sex (women 0.636; 0.517–0.783] men 0.480; 0.373–0.618]), vaccine status (vaccinated <2 doses 0.514; 0.435–0.608]), SUD subtypes (alcohol disorder 0.711; 0.511– 0.988], TUD 0.666; 0.555–0.800]) Omicron wave 0.624; 0.536–0.726). Our findings indicate could reduce treatment among support COVID‐19.

Язык: Английский

---

Effectiveness of nirmatrelvir/ritonavir and molnupiravir in non-hospitalized adults with COVID-19: systematic review and meta-analysis of observational studies

Journal of Antimicrobial Chemotherapy, Год журнала: 2024, Номер 79(9), С. 2119 - 2131

Опубликована: Май 31, 2024

To determine the effectiveness of nirmatrelvir/ritonavir and molnupiravir among vaccinated unvaccinated non-hospitalized adults with COVID-19.

Язык: Английский

---

Short- and long-term comparative effectiveness of nirmatrelvir/ritonavir and molnupiravir in asthma patients: a cohort study

Respiratory Research, Год журнала: 2025, Номер 26(1)

Опубликована: Фев. 28, 2025

Abstract Background Few studies evaluated the effectiveness of COVID-19 antivirals specifically in asthma population This study assessed short- and long-term effects nirmatrelvir/ritonavir versus molnupiravir population. Methods is a retrospective cohort on adult patients infected with COVID-19, using real-world data obtained from health officials Hong Kong. Key inclusion criteria were infection between March 16, 2022, Oct 30, 2023, age ≥ 18 years, previous diagnosis, prescription history an medication. Outcomes included acute post-acute mortality, all-cause hospitalization, cause-specific hospitalization. Results 1,745 eligible for this study, median follow-up time 365 days (IQR: 335–365). Patients group had significantly lower risks inpatient death (HR, 0·27 [95% CI, 0·12 to 0·59]; p = 0·0011), 0·49 0·28 0·85]; 0·011), hospitalization 0·72 0·58 0·89]; 0·0020), myocardial infarction 0·10 0·01 0·92]; 0·042) than control group. The risk was compared 0·65 0·52 0·81]; 0·00012). Among who prescribed medium-/ high-dose inhaled corticosteroids, hazard exacerbation 0·35 0·95]; 0.030). Conclusion Compared molnupiravir, may offer more benefits reducing sequelae among patients. In addition, also demonstrated mild asthma, which have not been generally recommended existing clinical management guidelines.

Язык: Английский

---

Real-life comparison of mortality in patients with SARS-CoV-2 infection at risk for clinical progression treated with molnupiravir or nirmatrelvir plus ritonavir during the Omicron era in Italy: a nationwide, cohort study

The Lancet Regional Health - Europe, Год журнала: 2023, Номер 31, С. 100684 - 100684

Опубликована: Июль 14, 2023

Comparative data on mortality in COVID-19 patients treated with molnupiravir or nirmatrelvir plus ritonavir are inconclusive. We therefore compared all-cause community-dwelling these drugs during the Omicron era.

Язык: Английский

---

Effectiveness of nirmatrelvir‐ritonavir on severe outcomes of COVID‐19 in the era of vaccination and Omicron: An updated meta‐analysis

Journal of Medical Virology, Год журнала: 2024, Номер 96(2)

Опубликована: Фев. 1, 2024

Abstract Nirmatrelvir‐ritonavir (NR) was approved to treat SARS‐CoV‐2 positive outpatients at high risk of progression severe disease, based on a randomized trial in unvaccinated patients. Effectiveness vaccinated patients and against Omicron has not yet been confirmed by clinical data, but recent meta‐analysis suggested good real‐world effectiveness 12 studies. We updated this searching Medline Embase databases for studies assessing NR mortality, hospitalization, composite outcome hospitalization and/or death, published between October 1, 2022 May 22, 2023. Random effects subgroup analysis performed. A total 32 were included the meta‐analysis. Pooled RR effect disease 0.36 (95% confidence interval [CI]: 0.25−0.52), 0.43 (CI: 0.37−0.51), 0.52 0.45−0.61) 0.54 0.41−0.73), respectively. indicated lower mortality (RR: 0.55, CI: 0.45−0.68), similar or 0.52, 0.58, 0.66, respectively). This robustly confirms protective COVID‐19 outcomes.

Язык: Английский

---

Comparison of effectiveness and safety of molnupiravir versus sotrovimab for COVID‐19: A systematic review and meta‐analysis

Immunity Inflammation and Disease, Год журнала: 2024, Номер 12(4)

Опубликована: Апрель 1, 2024

This systematic review and meta-analysis aimed to compare the effectiveness safety of molnupiravir sotrovimab in treatment patients with coronavirus disease 2019 (COVID-19).

Язык: Английский

---

Effectiveness of recently-approved oral antiviral medications on the outcome of patients with mild-to-moderate COVID-19 and pre–existing chronic obstructive pulmonary diseases

Expert Review of Anti-infective Therapy, Год журнала: 2024, Номер 22(11), С. 977 - 985

Опубликована: Май 4, 2024

Objectives This study assessed the effectiveness of oral antiviral agents nirmatrelvir – ritonavir (NMV-r) and molnupiravir (MOV) for treating mild-to-moderate coronavirus disease 2019 (COVID-19) in patients with COPD.

Язык: Английский

---

Clinical real-world effectiveness of nirmatrelvir/ritonavir for the treatment of SARS-CoV-2 infection: A meta-analysis

童綜合醫學雜誌, Год журнала: 2024, Номер 18(Suppl 1), С. S35 - S47

Опубликована: Авг. 8, 2024

Abstract Background: According to the Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients (EPIC-HR) study, compared with a placebo, nirmatrelvir/ritonavir significantly reduced risk coronavirus disease 2019 (COVID-19)-related hospitalization or mortality unvaccinated patients. The Delta variant was most prevalent severe acute respiratory syndrome 2 (SARS-CoV-2) among all treatment recipients EPIC-HR study. Omicron is less pathogenic than variant. efficacy partially fully immunized patients variant-related infections must be further evaluated. Objectives: current meta-analysis aimed evaluate therapeutic based on factors including hospitalization, all-cause mortality, and rebound who were against COVID-19. Methods: This It included 26 studies that directly examined clinical versus placebo adult SARS-CoV-2 infection caused by search criteria comprised keywords such as rebound. Results: 59% aged ≥65 years. However, their decreased only 36%. reduction similar between low high vaccination coverage. receiving had higher incidence those placebo. treated 53% 57%, respectively. Conclusion: indicates 57%

Язык: Английский

---

Antiviral Treatment in Older Chinese Patient with SARS-CoV-2 and Influenza A Virus Co-Infection: A Case Series

Infection and Drug Resistance, Год журнала: 2023, Номер Volume 16, С. 4763 - 4768

Опубликована: Июль 1, 2023

Coronavirus disease 2019 (COVID-19) emergence in late 2019, and wide spread quickly the world. In China, COVID-19 epidemic situation entered a low level now. With arrival of flu season, number patients with respiratory symptoms is increasing. We reported three cases who co-infected SARS-CoV-2 influenza A virus (IAV), they were all treated nirmatrelvir-ritonavir (NMV/r) baloxavir marboxil. Due to overlapping clinical features between two diseases, it important identified them gave antiviral therapy timely.

Язык: Английский

---